Publications by authors named "R C Ginestal"
To analyze the cost-effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.
View Article and Find Full Text PDFIntroduction: For more than a decade, after the ECTRIMS Congress, Spain has hosted the Post-ECTRIMS meeting, where neurologists with expertise in multiple sclerosis (MS) meet to review the new developments presented at the ECTRIMS.
Aim: This article, published in two parts, summarises the presentations of the post-ECTRIMS meeting, held online on 16 and 17 October 2020.
Development: This second part highlights the importance of gender and age in understanding the pathology of the disease and optimising its management.
Introduction: For more than a decade, following the ECTRIMS Congress, the Post-ECTRIMS Meeting has been held in Spain, where neurologists with expertise in multiple sclerosis (MS) from all over the country meet to review the most relevant latest developments presented at the ECTRIMS congress (on this occasion held together with ACTRIMS).
Aim: This article, published in two parts, summarises the presentations that took place at the Post-ECTRIMS Meeting, held online on 16 and 17 October 2020.
Development: This first part includes the latest results regarding the impact of the environment and lifestyle on risk of MS and its clinical course, and the role of epigenetics and genetic factors on these processes.
Article Synopsis
- The Post-ECTRIMS Meeting highlighted new research in multiple sclerosis, focusing on disease-modifying treatments, especially during pregnancy.
- Recent phase 3 trials assessed the safety and efficacy of ponesimod and ofatumumab for relapsing-remitting multiple sclerosis, while also reviewing existing and experimental treatments for progressive forms.
- There has been no significant progress in symptomatic treatments, but patients diagnosed recently show milder forms of the disease, possibly due to earlier diagnosis and more available treatments.
Introduction: Like every year, after the ECTRIMS Congress, renowned Spanish neurologists who are experts in multiple sclerosis presented the main novelties in research in this field at the Post-ECTRIMS Meeting.
Aim: To summarise the content presented at the 12th edition of the Post-ECTRIMS Meeting, which took place in September 2019 in Sevilla and is presented in two parts.
Development: This first part addresses the latest studies on vitamin D deficiency and the discrepancies that currently exist regarding its treatment.